Key facts
- It has raised $265.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($265.0M) in Aug 2021.
- 2 institutional filers report fund marks on Sonoma Biotherapeutics across 30 filings.
- Sonoma Biotherapeutics has filed 1 Form D with the SEC, most recently Aug 2021 ($265.0M sold to 40 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Sonoma Biotherapeutics
Create free account
No card required
Funding rounds
1 roundsAug 2021Early Stage VC (Series B)$265.0M▮
About Sonoma Biotherapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Sonoma Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Sonoma Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 30 fair-value marks on Sonoma Biotherapeutics between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.